Takara Bio Inc banner

Takara Bio Inc
TSE:4974

Watchlist Manager
Takara Bio Inc Logo
Takara Bio Inc
TSE:4974
Watchlist
Price: 1 143 JPY 0.09% Market Closed
Market Cap: ¥137.6B

Takara Bio Inc
Long-Term Debt

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Takara Bio Inc
Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
Takara Bio Inc
TSE:4974
Long-Term Debt
¥10B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
51%
3
3-D Matrix Ltd
TSE:7777
Long-Term Debt
¥275.8m
CAGR 3-Years
-57%
CAGR 5-Years
-23%
CAGR 10-Years
N/A
SanBio Co Ltd
TSE:4592
Long-Term Debt
¥1.1B
CAGR 3-Years
15%
CAGR 5-Years
-10%
CAGR 10-Years
0%
GNI Group Ltd
TSE:2160
Long-Term Debt
¥3B
CAGR 3-Years
167%
CAGR 5-Years
68%
CAGR 10-Years
20%
PeptiDream Inc
TSE:4587
Long-Term Debt
¥0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
O
Oncolys Biopharma Inc
TSE:4588
Long-Term Debt
¥76.4m
CAGR 3-Years
-22%
CAGR 5-Years
-27%
CAGR 10-Years
-13%
No Stocks Found

Takara Bio Inc
Glance View

Market Cap
137.6B JPY
Industry
Biotechnology

Takara Bio, Inc. engages in development and marketing of genetic engineering technologies. The company is headquartered in Kusatsu-Shi, Shiga-Ken and currently employs 1,539 full-time employees. The company went IPO on 2004-12-07. The firm operates in three business segments. Bioindustry Support segment provides reagents for research (genetic engineering reagents, cell engineering reagents, protein engineering reagents), scientific instruments, contract services and license fees for gene related patents to research institutes, such as universities and companies where biotechnology research and development are conducted. Gene Medicine segment provides gene therapy-related development and sale licensing fees and trial products as an application field of genetic engineering technology and cell engineering technology which is core technology cultivated in development of research reagents. Medical Food and Biotechnology segment provides health food and health food research and development services, license fees for health food related patents, as well as license fees for mushrooms.

Intrinsic Value
603.62 JPY
Overvaluation 47%
Intrinsic Value
Price ¥1 143

See Also

What is Takara Bio Inc's Long-Term Debt?
Long-Term Debt
10B JPY

Based on the financial report for Dec 31, 2025, Takara Bio Inc's Long-Term Debt amounts to 10B JPY.

What is Takara Bio Inc's Long-Term Debt growth rate?
Long-Term Debt CAGR 10Y
51%

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett